- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02496078
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Moscow, Den Russiske Føderation, 127015
- Local Institution
-
St. Petersburg, Den Russiske Føderation, 191167
- Local Institution
-
St.petersburg, Den Russiske Føderation, 190103
- Local Institution
-
-
-
-
-
Beijing, Kina, 100039
- Local Institution
-
-
Beijing
-
Beijing, Beijing, Kina, 100034
- Local Institution
-
Beijing, Beijing, Kina, 100050
- Local Institution
-
Beijing, Beijing, Kina, 100054
- Local Institution
-
Beijing, Beijing, Kina, 100015
- Local Institution
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510515
- Local Institution
-
Guangzhou, Guangdong, Kina, 510060
- Local Institution
-
-
Hebei
-
Shi Jia Zhuang, Hebei, Kina, 050051
- Local Institution
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Local Institution
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210002
- Local Institution
-
Nanjing, Jiangsu, Kina, 210029
- Local Institution
-
Nanjing, Jiangsu, Kina, 210003
- Local Institution
-
Zhenjiang, Jiangsu, Kina, 212000
- Local Institution
-
-
Jilin
-
Changchun, Jilin, Kina, 130021
- Local Institution
-
-
Liaoning
-
Shenyang, Liaoning, Kina, 110006
- Local Institution
-
Shenyang, Liaoning, Kina, 110002
- Local Institution
-
-
Shandong
-
Qingdao, Shandong, Kina, 266011
- Local Institution
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200025
- Local Institution
-
Shanghai, Shanghai, Kina, 200083
- Local Institution
-
Shanghai, Shanghai, Kina, 200062
- Local Institution
-
-
Shanxi
-
Xi'an, Shanxi, Kina, 710061
- Local Institution
-
Xi'an, Shanxi, Kina, 710038
- Local Institution
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Local Institution
-
-
-
-
-
Busan, Korea, Republikken, 47392
- Local Institution
-
Seoul, Korea, Republikken, 08308
- Local Institution
-
Seoul, Korea, Republikken, 07061
- Local Institution
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Patients chronically infected with HCV Genotype 1b
- No previous exposure to any interferon formulation, Ribavirin (RBV), and HCV direct acting antiviral agent
- HCV RNA viral load ≥ 10,000 IU/mL at screening
- Seronegative for HIV and HBsAg
- BMI of 18-35 kg/m2, inclusive
- Patients with compensated cirrhosis are permitted
Exclusion Criteria:
- Infection with HCV other than genotype (GT) -1b
- Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy
- Evidence of a medical condition contributing to chronic liver disease other than HCV
- Diagnosed or suspected hepatocellular carcinoma or other malignancies
- Uncontrolled diabetes or hypertension
- History of moderate to severe depression. Well-controlled mild depression is allowed
- Confirmed alanine aminotransferase (ALT) ≥ 5x Upper Limit of Normal (ULN)
- Confirmed platelet count < 50,000 cells/mm3
- Confirmed hemoglobin < 8.5 g/dL
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Active dual arm
Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48 |
Daclatasvir tablet 60mg
Asunaprevir soft capsule 100 mg
|
Placebo komparator: Placebo arm
Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60 |
Daclatasvir tablet 60mg
Asunaprevir soft capsule 100 mg
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Proportion of treated subjects randomized to Active Dual therapy with Sustained Virologic Response (SVR12)
Tidsramme: Post-treatment Week 12
|
HCV RNA < Lower limit of quantitation (LLOQ) target detected (TD) or target not detected (TND) at follow-up Week 12
|
Post-treatment Week 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Proportion of subjects with anemia on active Dual therapy
Tidsramme: Post-treatment Week 12
|
Post-treatment Week 12
|
Proportion of subjects with neutropenia on active Dual therapy
Tidsramme: Post-treatment Week 12
|
Post-treatment Week 12
|
Proportion of subjects with thrombocytopenia on active Dual therapy
Tidsramme: Post-treatment Week 12
|
Post-treatment Week 12
|
On treatment safety, as measured by frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)
Tidsramme: Post-treatment week 12
|
Post-treatment week 12
|
Differences in rates of selected Grade 3-4 laboratory abnormalities for hematology between treatments (DCV + Asunaprevir (ASV) vs PBO)
Tidsramme: first 12 weeks on treatment
|
first 12 weeks on treatment
|
Differences in rates of selected Grade 3-4 laboratory abnormalities for liver function between treatments (DCV + Asunaprevir (ASV) vs PBO)
Tidsramme: first 12 weeks on treatment
|
first 12 weeks on treatment
|
Proportion of subjects with SVR12 by the rs12979860 single nucleotide polymorphism (SNP) in the interleukin (IL) -28B gene for each cohort
Tidsramme: Post-treatment visit week 12
|
Post-treatment visit week 12
|
Proportion of subjects with hepatitis C virus (HCV) RNA < LLOQ-TD/TND in each arm at various intervals after the initiation of active Dual therapy
Tidsramme: post-treatment visit Week 24
|
post-treatment visit Week 24
|
Proportion of subjects who achieve HCV RNA < LLOQ-TND at each arm at various intervals after the initiation of active Dual therapy
Tidsramme: post-treatment visit Week 24
|
post-treatment visit Week 24
|
Proportion of treated subjects with SVR12 for subjects randomized to placebo
Tidsramme: Post-treatment visit week 12
|
Post-treatment visit week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Enterovirus infektioner
- Picornaviridae infektioner
- Hepatitis, kronisk
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Proteasehæmmere
- Asunaprevir
Andre undersøgelses-id-numre
- AI447-114
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis C
-
Tripep ABInovio PharmaceuticalsUkendtKronisk hepatitis C virusinfektionSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTrukket tilbageKronisk hepatitis C virusinfektionIsrael
-
Hadassah Medical OrganizationUkendtKronisk hepatitis C virusinfektionIsrael
-
Beni-Suef UniversityAfsluttetKronisk hepatitis C virusinfektionEgypten
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV) | Hepatitis C viral infektionForenede Stater, New Zealand
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 4 | Hepatitis C viral infektionForenede Stater
-
Humanity and Health Research CentreBeijing 302 HospitalAfsluttetKronisk hepatitis C-infektionKina
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVie (prior sponsor, Abbott)AfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV)Forenede Stater, Australien, Canada, Frankrig, Tyskland, New Zealand, Puerto Rico, Spanien, Det Forenede Kongerige
-
AbbVieAfsluttetHepatitis C virus | Kronisk hepatitis C-virus
Kliniske forsøg med Daclatasvir
-
Atea Pharmaceuticals, Inc.AfsluttetHepatitis C virusinfektion | Hepatitis C | Hepatitis C, kronisk | Kronisk hepatitis C | HCV-infektionBelgien, Mauritius, Moldova, Republikken
-
Vertex Pharmaceuticals IncorporatedAfsluttetHepatitis C | Kronisk hepatitis C | HCV | CHCNew Zealand
-
Bristol-Myers SquibbAfsluttetHepatitis CForenede Stater
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Afsluttet
-
Genuine Research Center, EgyptZeta Pharma Pharmaceutical IndustriesAfsluttet
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Afsluttet
-
Ain Shams UniversityRekrutteringKronisk HCV-infektionEgypten
-
Nanjing Sanhome Pharmaceutical, Co., Ltd.Ukendt
-
Bristol-Myers SquibbAfsluttetKronisk hepatitis CForenede Stater, Puerto Rico
-
ANRS, Emerging Infectious DiseasesAfsluttetHepatitis C | Viral hepatitis C | StofbrugVietnam